{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115937","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.121890+00:00","generated_at":"2026-06-22T02:36:29.777599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novavax Q3 revenue $735M, net loss $169M; narrows FY 2022 revenue guidance to ~$2.0B","bullets":["Total revenue $735M (Q3 2021: $179M); net loss $169M vs $322M prior year.","Cost of sales $435M includes $249M excess/obsolete inventory losses.","Refines FY 2022 revenue guidance to ~$2.0B, low end of prior $2.0-2.3B range.","Over 94M doses of COVID-19 vaccine delivered globally; booster authorized in U.S., EU, others.","Cash and restricted cash $1.3B as of Sept 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115937","json":"https://secwatch.observer/filing/0001104659-22-115937.json","markdown":"https://secwatch.observer/filing/0001104659-22-115937.md","text":"https://secwatch.observer/filing/0001104659-22-115937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/tm2230063d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:36:29.777599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63de8330140cf17fc91f187447fca2909a61c11a","claim":"NOVAVAX INC reported the third quarter ended September 30, 2022 results: revenue $735 million.","evidence_excerpt":"· Achieved total revenue for the third quarter of $735 million · Delivered over 94 million doses of NVX-CoV2373 globally to date · Authorized as a booster for adults in the U.S., E.U., and additional markets · Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets · Announced data about our prototype’s broad immune response against circulating variants when used as a booster · Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of age · Refining full year 2022 total revenue guidance to approximately $2.0 billion · Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., November 8, 2022 – Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$735 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}